Current Report Filing (8-k)
10 May 2016 - 9:46PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
May
10, 2016
ARIAD
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
001-36172
|
22-3106987
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(I.R.S.
Employer
Identification
No.)
|
26 Landsdowne Street, Cambridge,
Massachusetts
|
02139
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant's telephone number, including
area code:
(617) 494-0400
Not
Applicable
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions
(
see
General Instruction A.2.
below)
:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM 2.02
|
Results of Operations and Financial Condition.
|
In a press release dated May 10, 2016, ARIAD Pharmaceuticals, Inc.
(the “Company”) announced financial results for the first quarter
ended March 31, 2016, issued 2016 financial guidance, and provided
an update on corporate developments and its ongoing strategic
review. A copy of the press release is attached hereto as Exhibit
99.1. The information under the headings “2016 First Quarter
Financial Results” (other than the information under “2016
Financial Guidance”), “Today’s Conference Call at 8:30 a.m. ET”
and the condensed consolidated financial information included in
the press release are incorporated by reference into this Item
2.02 of this Current Report on Form 8-K.
|
ITEM 7.01
|
Regulation FD Disclosure.
|
In the press release dated May 10, 2016, the Company also provided
2016 financial guidance, as well as information on upcoming
meetings. The information set forth under the headings “2016
Financial Guidance” and “Upcoming Meetings” in the press release
are incorporated by reference into this Item 7.01 of this Current
Report on Form 8-K.
|
In the press release dated May 10, 2016, the Company also provided
an update on its Iclusig®, brigatinib and pipeline programs. The
second paragraph of the press release and the information set
forth under the heading “Recent Progress and Key Objectives,”
together with the forward-looking statement disclaimer at the end
of the press release, are incorporated by reference into this Item
8.01 of this Current Report on Form 8-K.
|
ITEM 9.01
|
Financial Statements and Exhibits.
|
|
Exhibit
|
Description
|
|
99.1
|
Press release dated May 10, 2016
|
The press release may contain hypertext links to information on
our websites. The information on our websites is not incorporated
by reference into this Current Report on Form 8-K and does not
constitute a part of this Form 8-K.
|
|
The portions of the press release incorporated by reference into
Item 8.01 of this Current Report on Form 8-K are being filed
pursuant to such item. The remaining portions of the press release
are being furnished pursuant to Items 2.02 and 7.01 of this
Current Report on Form 8-K and shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”) or otherwise subject to the
liabilities of that Section, nor shall they be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act except as shall be expressly set
forth by specific reference in such filing.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
ARIAD Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Manmeet S. Soni
|
|
|
|
|
|
Manmeet S. Soni
|
|
|
|
|
|
Executive Vice President, Chief Financial Officer
|
|
|
|
|
|
Date:
|
May 10, 2016
|
|
|
|
Exhibit List.
Exhibit
|
Description
|
|
|
99.1
|
Press release dated May 10, 2016
|
4
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Apr 2024 to May 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Ariad Pharmaceuticals, Inc. (NASDAQ): 0 recent articles
More Ariad Pharmaceuticals Inc News Articles